Tome Biosciences: What Went Wrong and How to Avoid Their Fate
The Rise and Fall of Tome Biosciences Tome Biosciences launched in December 2023 with an ambitious goal: to revolutionize gene editing through their innovative Programmable Genomic Integration (PGI) platform. Backed by $213 million in Series A and B funding, Tome aimed to precisely insert large DNA sequences into the human genome without causing double-stranded breaks—a …
Tome Biosciences: What Went Wrong and How to Avoid Their Fate Read More »